Showing results (21-30 of 90) with videos related to
Sort By:
Pageof 9
Plos One|April 13, 2012
Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patientAlessandra Sottini, Ruggero Capra, Cinzia Zanotti, et al.Annals of Neurology|October 13, 2017
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathyCristina Scarpazza, Luca Prosperini, Nicola De Rossi, et al.European Journal of Internal Medicine|May 15, 2020
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumoniaRuggero Capra, Nicola De Rossi, Flavia Mattioli, et al.Current Neuropharmacology|March 31, 2021
Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical ViewpointMarika Alborghetti, Gianmarco Bellucci, Antonietta Gentile, et al.Journal of Neuroimmunology|May 17, 2008
Modulation of IFNAR1 mRNA expression in multiple sclerosis patientsFederico Serana, Alessandra Sottini, Claudia Ghidini, et al.Journal of Neuropsychology|September 12, 2017
Altered bodily self-consciousness in multiple sclerosisElena Nava, Flavia Mattioli, Chiara Gamberini, et al.Journal of the Neurological Sciences|March 19, 2002
Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated small vessel vasculitidesFlavia Mattioli, Ruggero Capra, Marco Rovaris, et al.Journal of Neurovirology|August 31, 2019
Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathyClaudia Piu, Gabriele Ibba, Diego Bertoli, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|September 28, 2013
Changes of brain resting state functional connectivity predict the persistence of cognitive rehabilitation effects in patients with multiple sclerosisLaura Parisi, Maria A Rocca, Flavia Mattioli, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 5, 2020
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumabChiara Rosa Mancinelli, Cristina Scarpazza, Cinzia Cordioli, et al.Pageof 9